Gene Therapy Program

The Gene Therapy Program (GTP) is a research and development organization within the University of Pennsylvania's Perelman School of Medicine. It is focused on the development and commercialization of gene therapy and associated technologies.

Organization

Gene Therapy Program - Team²⁾
Name	Position	Notes
James Wilson	Director	Orphan Disease Center, Perelman School of Medicine, iECURE, Whitehead Institute, Health through Fitness in Orphan Diseases
Antony Appleyard	Executive Director, Regulatory Affairs	Diamond Pharma Services, Novacta Biosystems, Royal Society of Chemistry, The Organisation for Professionals in Regulatory Affairs (TOPRA)
Fabian Chen	Chief Medical Officer	Rocket Pharmaceuticals, Novartis, Merck, University of California Los Angeles
Jenny Greig	Senior Research Director, Translational Research	American Society for Gene and Cell Therapy
Juliette Hordeaux	Senior Research Director, Translational Research	-
Lori Kellam	Senior Director, Research Portfolio Management	Temple University
Mike LaBruto	Executive Director, Quality Assurance	GlaxoSmithKline, Temple University School of Pharmacy
Thomas Logan	Chief Strategy and Business Officer	BTG
Monique Molloy	Chief Administrative Officer	Orphan Disease Center (ODC)
William Singleton	Executive Director, Program for Comparative Medicine	Animal Care Training Services (ACTS)
Simin Zaidi	Chief Technology Officer	Catalent Biologics

¹⁾

Our Mission & History. University of Pennsylvania Gene Therapy Program. Retrieved May 22, 2023, from https://web.archive.org/web/20230522003917/https://gtp.med.upenn.edu/about/our-mission-history

²⁾

Our Team. University of Pennsylvania Gene Therapy Program. Retrieved May 22, 2023, from http://archive.today/2023.05.22-003614/https://gtp.med.upenn.edu/about/our-team